effect of milk thistle extract, curcumin, n-acetylcystein, artichoke extract, vitamin D, and Chromium on non-alcoholic fatty liver

Assessing the synergistic effect of milk thistle extract, curcumin, n-acetylcystein, artichoke extract, vitamin D, and Chromium compared to placebo on liver function in patients with non-alcoholic fatty liver (NAFLD)

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20140804018677N27

Enrollment

Registered

2023-08-19

Start date

2023-09-06

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty liver. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: ?Supplement (1000 mg), Samanic company, daily for12 weeks. Intervention 2: Control group: Placebo contain maltodextrine, (1000 mg), Samanic company, daily for12 wee

Eligibility

Sex/Gender

All

Age

18 Days to No maximum

Inclusion criteria

Inclusion criteria: Fatty liver diagnosis based on sonography Age>18 years Willing to participate in the study

Exclusion criteria

Exclusion criteria: Having known kidney disease Having known heart disease Pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
Alanine Aminotransferase (ALT) enzyme. Timepoint: Baseline and at the end of the study. Method of measurement: Biochemical kit.;Aspartate transaminase (AST) enzyme. Timepoint: Baseline and at the end of the study. Method of measurement: Biochemical kit.;Fibrosis-4 (FIB-4). Timepoint: Baseline and at the end of the study. Method of measurement: Biochemical kit.;AST to Platelet Ratio Index (APRI). Timepoint: Baseline and at the end of the study. Method of measurement: Calculation based on biochemical kit.;Alkaline phosphatase (Alk-ph) enzyme. Timepoint: Baseline and at the end of the study. Method of measurement: Biochemical kit.	—

Measure

Time frame

Alanine Aminotransferase (ALT) enzyme. Timepoint: Baseline and at the end of the study. Method of measurement: Biochemical kit.;Aspartate transaminase (AST) enzyme. Timepoint: Baseline and at the end of the study. Method of measurement: Biochemical kit.;Fibrosis-4 (FIB-4). Timepoint: Baseline and at the end of the study. Method of measurement: Biochemical kit.;AST to Platelet Ratio Index (APRI). Timepoint: Baseline and at the end of the study. Method of measurement: Calculation based on biochemical kit.;Alkaline phosphatase (Alk-ph) enzyme. Timepoint: Baseline and at the end of the study. Method of measurement: Biochemical kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSoodeh Razghei Jahromi

Shahid Beheshti University of Medical Sciences

soodehrazeghi@gmail.com+98 21 2235 7483

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026